Patients with recurrent and/or metastatic head and neck cancer with high-risk HPV16 infection are needed for a study to research an investigative therapy in combination with immunotherapy

UVA Tracking #
Principal Investigator
Varinder Kaur
Contact Phone
Official Trial Title
A phase II, open-label, multi-center study of PDS0101 (immunoMAPK-RDOTAP/HPV-16 E6 & E7 Peptides) and pembrolizumab (KEYTRUDA) combination immunotherapy as a first line treatment in subjects with recurrent and/or metastatic head and neck cancer and high-r
Study Description

The University of Virginia Cancer Center is conducting a clinical research study for patients who are adults ages 18 and over, and recurrent and/or metastatic head and neck cancer with high risk HPV16 infection. The purpose of this study to evaluate the combination of an investigational drug (PDS0101) and an immunotherapy drug (pembrolizumab) in patients with high risk HPV16 positive head and neck cancer. The effects of the investigational and immunotherapy drug combination will be evaluated for this study.

Participation includes a screening period, up to 35 cycles of treatment (cycle= 3 weeks), with a longer term follow-up via a clinic visit or a phone call to keep track of how you’re doing. Study specific test will be provided at no cost to you.

Additional information can be found here:


o Reimbursement: You will receive up to $.54 per mile for travel and up to $175 for per night for hotel.


No Compensation